Amyotrophic Lateral Sclerosis (ALS) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Amyotrophic Lateral Sclerosis (ALS) Emerging Therapy and TPP Insights

Thelansis’s “Amyotrophic Lateral Sclerosis (ALS) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Amyotrophic Lateral Sclerosis (ALS) Overview

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder marked by the progressive loss of upper and lower motor neurons across the motor cortex, brainstem, and spinal cord. This cellular destruction triggers spreading muscular paralysis, eventually culminating in respiratory failure. While the exact trigger remains elusive, the underlying pathology involves a complex mix of TDP-43 and SOD1 protein misfolding, glutamate excitotoxicity, neuroinflammation, and mitochondrial collapse. Around 10% of cases are heritable—primarily tied to C9orf72, SOD1, FUS, and TARDBP mutations—while the vast majority are sporadic. Patients usually notice insidious focal weakness, split between limb-onset (wasting, twitching) and bulbar-onset (slurred speech, swallowing difficulties), often accompanied by hyperreflexia and, in many cases, frontotemporal cognitive changes. Diagnosis relies on Gold Coast or revised El Escorial criteria, verified by electromyography showing widespread denervation. Mechanistic treatments remain a steep challenge: riluzole and edaravone offer modest extension of function, but the approval of tofersen for SOD1 mutations shattered paradigms by proving that antisense oligonucleotides can aggressively lower neurofilament light chain biomarkers and slow neurodegeneration. Furthermore, the industry has entirely moved past failed legacy drugs like Relybrio—which was withdrawn from the market—shifting modern pipeline focus toward advanced clinical assets targeting TDP-43 stabilization, stathmin-2 restoration, and neuroinflammatory pathways. Multidisciplinary care via non-invasive ventilation, feeding tubes, and proactive symptom management remains the bedrock of treatment, supporting patients through a highly variable survival window while preserving quality of life.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Read more: Amyotrophic Lateral Sclerosis (ALS) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026